Abstract:Louis Chhor, 1, 2 Stefan Saggese, 2 Garun S Hamilton, 1, 3 Martin Ian MacDonald 1 1 Monash Lung, Sleep, Allergy & Immunology, Monash Health, Melbourne, Victoria, Australia; 2 Department of General Medicine, Monash Health, Melbourne, Victoria, Australia; 3 School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia Correspondence: Louis Chhor, Department of General Medicine, Dandenong Hospital, 135 David St, Dandenong, VIC, 3175, Australia, Tel +61 3 9544 1000, Email Objective: To compare clinical characteristics and outcomes of hospitalized acute exacerbations of COPD (AECOPD)s secondary to SARS-CoV-2 versus other respiratory viruses amongst a highly vaccinated population in the Omicron era. Design: Retrospective cohort study; analysis of hospital medical records and linked pathology and radiology reports. Setting: Tertiary health network in Victoria, Australia; January 2022–August 2022. Main Outcome Measures: Key clinical information including comorbidities, vaccination status, treatments administered and outcomes such as hospital length of stay, ICU admission, non-invasive ventilation usage and inpatient mortality. Results: One hundred ninety-nine viral AECOPDs - 125 SARS-CoV-2 and 74 other viruses were identified. Of the SARS-CoV-2 group. 13.6% were unvaccinated, 17.6% partially and 68.0% fully vaccinated. The SARS-CoV-2 group were older (77.2 vs 68.9, p < 0.00001) with more comorbidities (1[1– 2] vs 1[0– 2], p = 0.008) and lower candidacy for full resuscitation (25.6% vs 56.8%, p < 0.0001). Mortality tended to be higher among SARS-CoV2 admission (9.6% v 2.7%, p = 0.066) but rates of ICU admission (10.4% v 13.5%, p = 0.507), length of hospitalisation (5[3– 8] vs 5[3– 9], p = 0.9) and readmission within 30 days (25% vs 33.3%, p = 0.184) were similar. Conclusion: In a highly vaccinated population in the Omicron era, COPD patients requiring hospitalisation with SARS-CoV-2 are older with more comorbidities than those admitted with other respiratory viruses. Length of hospitalisation and ICU utilisation was similar. Inpatient mortality may be higher. Keywords: SARS-CoV2, coronavirus, COPD, viral exacerbations Patients with chronic obstructive pulmonary disease (COPD) are vulnerable to severe acute exacerbations (AECOPDs) when they contract respiratory viruses. 1 Exacerbations of COPD are cardinal events in the disease, associated with accelerated decline in lung function, reduced quality of life, hospitalization and mortality. 2–4 Viral infection appears to be responsible for up to 50% of AECOPDs. 5,6 The prognosis of virus-associated exacerbation appears different to other exacerbation etiotypes, with a slower recovery and prolonged hospitalization. 7,8 In general, studies examining hospitalized AECOPDs have considered all respiratory viruses as a generic grouping, with outcomes compared between "viral" and "non-viral" exacerbations or versus alternative broad etiologies such as bacterial or eosinophilic exacerbations. 9–11 Studies of individual viruses such as rhinovirus ("common cold"), influenza and Respiratory Syncytial Virus (RSV) have been performed, although there are very limited data to indicate whether specific respiratory viruses have different impacts as causes of severe AECOPDs. The relative impact of SARS-CoV-2 versus previously circulating respiratory viruses as a cause of severe AECOPD has been little studied. One prospective observational cohort study in the United Kingdom compared outcomes from AECOPDs secondary to SARS-CoV-2 versus groups with either alternative infections (bacterial or viral), or non-infective AECOPDs. 10 They reported higher 30-day mortality, longer hospital stays and more frequent requirement for positive pressure ventilatory support among the SARS-CoV-2 group. Much of this data was collected during the early phases of the pandemic with circulating wild-type, alpha and delta strains. Since the onset of the COVID pandemic, widespread vaccination and development of effective therapeutics have been achieved, limiting applicability of early pandemic data to the current era. SARS-CoV-2 is now an endemic community respiratory virus, and it is therefore necessary to evaluate the clinical phenotype of AECOPD secondary to SARS-CoV-2 contextualized alongside other commonly circulating respiratory viruses. We hypothesized that sub-populations of COPD patients may be more vulnerable when hospitalized with AECOPD due to SARS-CoV-2 compared to other respiratory viruses, which may inform and guide clinical management, prevention strategies and prognosis. We therefore analyzed hospi -Abstract Truncated-

Clinical outcomes in patients with COPD hospitalized with SARS-CoV-2 versus non- SARS-CoV-2 community-acquired pneumonia

Combined Clinical and Imaging Features Better Predict the Critical Outcomes of Patients with SARS-COV-2.

Characterisation and outcomes of ARDS secondary to pneumonia in patients with and without SARS-CoV-2: a single-centre experience

COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis

Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia

Clinical Characteristics and Outcomes of Hospitalized AECOPDs Secondary to SARS-CoV-2 versus Other Respiratory Viruses

Respiratory Interventions, Hospital Utilization, and Clinical Outcomes of Persons with COPD and COVID-19

[Comparative Analysis of Clinical Features Between Severe Coronavirus Disease 2019 and Severe Community Acquired Pneumonia].

Characteristics and Prognosis of COVID-19 in Patients with COPD

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: a multicenter, retrospective, observational study

In-Hospital mortality for immunocompromised patients with SARS-CoV-2 community-acquired pneumonia (CAP)

Outcomes among patients with chronic obstructive pulmonary disease after recovery from COVID-19 infection of different severity

Impact of the COVID-19 pandemic on the clinical features of patients with chronic obstructive pulmonary disease: an observational cross-sectional study

Comparison of clinical outcomes in hospitalized patients with COVID-19 or non-COVID-19 community-acquired pneumonia in a prospective observational cohort study

Comparison of Clinical Features and Outcomes between SARS-CoV-2 and Non-SARS-CoV-2 Respiratory Viruses Associated Acute Respiratory Distress Syndrome: Retrospective Analysis

Comparing Clinical Features and Outcomes in Mechanically Ventilated Patients with COVID-19 and Acute Respiratory Distress Syndrome

Chronic Obstructive Pulmonary Disease and the Omicron Variant of COVID-19 Prognosis: A Retrospective Cohort Study

Outcomes of Patients with Active Cancers and Pre-Existing Cardiovascular Diseases Infected with SARS-CoV-2

[Severity of community-acquired pneumonia due to coronavirus SARS-CoV-2 in immunocompetent hospitalized adult patients]

COVID-19, COPD, and AECOPD: Immunological, Epidemiological, and Clinical Aspects